Company Overview and News

142
Walgreens wants to be seen as a health-care company, not just a retailer

4h cnbc
Its competitor, CVS Health, has been touting itself as a health-care company dedicated to transforming the patient experience and lowering costs in the process. To help its case, CVS is acquiring insurer Aetna and hopes to close the deal sometime in the fourth quarter.
RAD DTK CVS

15
Amid Controversy in Drug Pricing on TV Ads, Biopharma Industry Argues Free Speech

2018-10-16 biospace
As part of the Trump Administration’s “blueprint” to bring down drug prices, a policy of requiring drug companies to list prices in advertisements is being floated. In a speech by Department of Health and Human Services Secretary Alex Azar before the National Academy of Medicine, Azar discussed the proposed legislation.
REGN CI CVS

10
Merger Arbitrage Mondays - October 15, 2018

2018-10-16 seekingalpha
Aetna and CVS Health Corporation entered into a consent decree with the United States Department of Justice.
CALL CVS COL AET

18
UPDATE 1-UnitedHealth tops earnings estimates, raises 2018 forecast

2018-10-16 reuters
(Reuters) - UnitedHealth Group Inc added more members to its health plans in the third quarter, helping it to post a profit well above Wall Street estimates and boost its earnings forecast for the year.
CI CVS AET UNH

63
2 Brick-and-Mortar Retail Stocks to Buy Now

2018-10-15 investorplace
It’s unlikely you’re a mall rat in this age of e-commerce shopping, but despite the high-profile death of Sears (NASDAQ:SHLD), two brick-and-mortar shops actually have figured out how to compete in this environment. These retail stocks are Foot Locker (NYSE:FL) and Ulta Beauty Salon (NASDAQ:ULTA).
SHLD AMZN NKE ULTA FL CVS

49
In a Cold Market, Walmart Stock Is Hot

2018-10-15 investorplace
As the stock market has cooled in October, the stability of Walmart (NYSE:WMT) has made it a hot stock. The rally began in August after the company reported 4.5% growth in U.S. year-over-year sales . Since then, the shares are up about 8%, while the average Nasdaq stock is down 4%.
DB AMZN PYPL AXP CVS HUM AET WMT

9
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?

2018-10-15 zacks
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering CVS Health (CVS - Free Report) , which belongs to the Zacks Retail - Pharmacies and Drug Stores industry.
CVS

34
Healthcare 16-24% Target Net Gains Pace WallStars For October

2018-10-15 seekingalpha
Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides.
GRFS GILD AZN DGX CVS GSK SNY STE AZN AGN NVO PMD NVS OMI GSK ABBV CAH ABBV

18
Stocks Holding Up Market

2018-10-15 seekingalpha
Nearly one-third of the S&P 500 constituents are in bear market territory, trading 20% off their 52-week highs.
AAPL AVGO MSFT CAIAF CI CVS CA AET

12
Walgreens: High Yielder

2018-10-14 seekingalpha
The market is focused too much on comp sales and the Amazon fears that the cheap valuation is ignored.
WBA CVS AET

44
DOJ Approval Means Time to Take Profits on Aetna Stock

2018-10-13 investorplace
In late October 2017, U.S. drugstore operator CVS Health Corp (NYSE:CVS) announced intentions to acquire U.S. health insurer Aetna Inc (NYSE:AET) in a $69 billion dollar deal that promised to permanently alter the healthcare industry. The deal underwent broad scrutiny from regulators. But, fast forward a year, and that deal is finally being approved by the Department of Justice.
AMZN CVS AET

28
CVS Health Is Still A Buy - Cramer's Lightning Round (10/11/18)

2018-10-12 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, October 11.
D VOD AEP OGS ARNC CVS

9
CVS and Aetna Cleared for Merger as Companies Tighten Leadership Roles

2018-10-11 biospace
The U.S. Department of Justice has given preliminary approval for CVS’ $69 billion acquisition of Aetna after Aetna divested its Medicare Part D business.
WCG CVS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CVS / CVS Health Corporation on message board site Silicon Investor.

cvs cvs cvs CVSN: ChromaVision Medical Sys. CVSN: ChromaVision Medical Sys. CVSN: ChromaVision Medical Sys.
ChromaVision Med. Sys. (CVSN) ChromaVision Med. Sys. (CVSN) ChromaVision Med. Sys. (CVSN) CVS Corp CVS Corp CVS Corp
CUSIP: 126650100